Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of pseudomonas infections
3.2.1.2 Advancements in diagnostic technologies
3.2.1.3 Ongoing research and development activities focused on creating new antibiotics
3.2.2 Industry pitfalls & challenges
3.2.2.1 Rise in antibiotic resistance
3.2.2.2 Potential for severe side effects and adverse reaction
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Monotherapy
5.3 Combination therapy
Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Aminoglycosides
6.3 Cephalosporins
6.4 Carbapenems
6.5 Monobactams
6.6 Other drug types
Chapter 7 Market Estimates and Forecast, By Type of Infection, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Respiratory tract infections
7.3 Urinary tract infections (UTIs)
7.4 Bloodstream infections
7.5 Skin and soft tissue infections
7.6 Eye & ear infections
7.7 Other types of infections
Chapter 8 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Branded
8.3 Generics
Chapter 9 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Oral
9.3 Parenteral
9.4 Other routes of administration
Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 Hospital pharmacies
10.3 Retail pharmacies
10.4 Online pharmacies
Chapter 11 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
11.1 Key trends
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Poland
11.3.7 Netherlands
11.3.8 Rest of Europe
11.4 Asia Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 Australia
11.4.5 South Korea
11.4.6 Rest of Asia Pacific
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest of Latin America
11.6 Middle East and Africa
11.6.1 South Africa
11.6.2 Saudi Arabia
11.6.3 UAE
11.6.4 Rest of Middle East and Africa
Chapter 12 Company Profiles
12.1 AbbVie Inc.
12.2 AstraZeneca PLC
12.3 Bristol Myers Squibb Company
12.4 Baxter International Inc.
12.5 Lupin Pharmaceuticals Inc.
12.6 Merck & Co. Inc.
12.7 Neopharma
12.8 Novartis AG
12.9 Pfizer Inc.
12.10 Sanofi SA
12.11 Shionogi & Co., Ltd.
12.12 Teva Pharmaceutical Industries Ltd.
